Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain Teresa Barcina LacostaArnold G. VultoSteven Simoens Commentary 26 February 2024 Pages: 325 - 329
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching Hillel P. CohenWolfram Bodenmueller Current Opinion Open access 23 March 2024 Pages: 331 - 339
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab Kouhei TsumotoTsutomu Takeuchi Review Article Open access 08 April 2024 Pages: 341 - 351
Research Advances in Stem Cell Therapy for Erectile Dysfunction Wei WangYing LiuCong-hui Han Review Article Open access 23 March 2024 Pages: 353 - 367
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight Zhenjie ZhangSiqi ZhangBo Feng Review Article Open access 15 March 2024 Pages: 369 - 385
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance Muhammad Shahzad RafiqMuhammad AbuBakar ShabbirHaihong Hao Review Article 11 April 2024 Pages: 387 - 404
Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies Noraisyah Mohd SaniZoriah AzizAdeeba Kamarulzaman Systematic Review 12 March 2024 Pages: 405 - 423
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database Paola Maria CutroneoElena ArzentonGianluca Trifirò Original Research Article Open access 15 March 2024 Pages: 425 - 448
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region Khalid A. AlnaqbiNasra Al AdhoubiTore K. Kvien Original Research Article Open access 25 February 2024 Pages: 449 - 463
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs Tess MartinCatherine RioufolIsabelle Borget Original Research Article 20 April 2024 Pages: 465 - 475